Global VONVENDI Drug Market Share, Size, Analysis, Growth, Report, Foreacst: By Indication: On-demand treatment and control of bleeding episodes, Perioperative management of bleeding, Routine prophylaxis, Type 3 Von Willebrand Disease (VWD), Others; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2023-2031

Global VONVENDI Drug Market Outlook

The VONVENDI drug market size is likely to grow in the forecast period of 2023-2031, driven by the rising prevalence of Von Willebrand disease (VWD). VONVENDI drug is widely used in the treatment of Von Willebrand disease (VWD), a blood disorder, which is likely to affect about 1% of the population in the coming years.

VONVENDI Drug Market: Insights

Adults with Von Willebrand disease (VWD), an inherited blood disorder that makes it challenging to form blood clots, can use VONVENDI® to manage bleeds. The only and first treatment for VWD that is recombinant, or created without using human blood, is VONVENDI. There is almost no chance that recombinant goods will come into contact with a disease that can be contracted through contact with contaminated human blood.

A blood glycoprotein, called von Willebrand factor, especially affects platelet adherence during haemostasias. It has a role in a variety of illnesses, including von Willebrand disease, thrombotic thrombocytopenic purpura, Heyde's syndrome, and perhaps hemolytic-uremic syndrome.

Since the symptoms are subtle or nonexistent, many people with von Willebrand disease are unaware of it. Abnormal bleeding is the condition's most typical symptom. The symptoms come in three primary forms. Depending on the nature and severity of the disease, different people experience different amounts of bleeding.

There are different types of this disease:

• Type 1: It is the most prevalent and mildest type. Von Willebrand factor levels are lower in the blood of those with type 1 VWD. Bleeding is typically just a concern after surgery, when you get hurt, or when you get a tooth out.

• Type 2: The Von Willebrand factor malfunctions in those with this kind of VWD. Compared to type 1, bleeding tends to be greater and more frequent.

• Type 3: The most severe and uncommon kind is type 3. Von Willebrand factor is either very low or absent in people. It is typical to have bleeding from the mouth, nose, and stomach, and injuries can also cause joint and muscle bleeding.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

VONVENDI Drug Market Segmentations:

The market can be categorized into the following sections:

Market Breakup by Indication

• On-demand treatment and control of bleeding episodes

• Perioperative management of bleeding
  • Elective Surgical Procedure
  • Emergency Surgery
• Routine prophylaxis

• Type 3 von Willebrand disease (VWD)

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Market Breakup by End User

• Hospitals and Clinics

• Research and Academic Laboratories

• Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

VONVENDI Drug Market: Epidemiology

Men and women both experience Von Willebrand disease (VWD), which can afflict up to 1% of the general population. However, due to the increased bleeding that VWD causes during menstruation, pregnancy, and postpartum, women are more prone to suffer its symptoms. More than 14,600 men, women, and kids received treatment for VWD between 2012 and 2016 at Haemophilia treatment facilities. Women and girls made up about two-third of the total count.

Von Willebrand disease (VWD) is estimated to affect between 0.6 and 1.3% of the general population (in all its variants), however, only around 1/10 000 people have symptomatic VWD that needs special care. One in one million is the rarity of Type 3 VWD.

The market for Von Willebrand disease treatments is dominated by North America because of its sophisticated healthcare system. A significant rate of increase is anticipated in Asia Pacific in the coming years as the region is expanding their health care infrastructure.

Emergent Treatments and Initiatives in the VONVENDI Drug Market

Different patient aid programmes are being introduced by several businesses, associations, and organisations for those who have been impacted by von Willebrand disease or associated bleeding diseases. By raising public knowledge of the condition, aiding in diagnosis and treatment, these patient assistance initiatives have had a positive effect on the management of von Willebrand disease. This, in turn, has increased the demand for von Willebrand disease treatments worldwide.

For instance, 2020, Domedica and Octapharma AG collaborated to create the WiCare programme, which offers at-home assistance to individuals with von Willebrand disease (vWD).

Therapeutic Landscape of von Willebrand Disease

Von Willebrand factor deficit or dysfunction results in Von Willebrand disease, an inherited bleeding illness. A plasma protein called VWF is what causes platelets to initially adhere to vascular damage sites. Additionally, this protein stabilizes clotting factor VIII (FVIII) in the blood by binding to it.

Menorrhagia, nose, gum bleeding, and protracted bleeding from skin wounds are among the major symptoms of von Willebrand disease. Due to an increase in patient assistance programmes, a promising medication pipeline, and recent drug approvals, the market for von Willebrand disease treatments has grown dramatically over the past ten years.

Desmopressin, clot-stabilizing drugs, replacement therapy, contraceptives, and other medicines are widely used in the treatment of von Willebrand disease. Desmopressin is one of the most common treatments used for von Willebrand disease.

Desmopressin, a primary medication, is frequently supplied via injection, and replacement therapies are also given in this way. During an emergency, injections react very rapidly and are a very efficient medicine delivery method. As a result, during the projected period, the market is also anticipated to grow at a fast pace.

Supplier Landscape of the VONVENDI Drug Market

The VONVENDI drug market report gives an in-depth analysis of the key suppliers involved in the market, sponsors manufacturing the drugs. The key suppliers included in the market are as follows:

• Baxalta US Inc.

• Takeda Pharmaceutical Company Limited

Key Highlights of the Report

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.